Avanafil
- TRADE NAME: Stendra (Vivus)
- INDICATIONS: Erectile dysfunction
- CLASS: Phosphodiesterase type 5 (PDE5) inhibitor
- HALF-LIFE: 5 hours
FDA APPROVAL DATE: 04/27/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alcohol, Alpha blockers, Amprenavir, Antihypertensives, Aprepitant, Atazanavir, Clarithromycin, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Nitrates, Ritonavir, Saquinavir, Strong CYP3A4 inhibitors, Telithromycin, Verapamil, Viloxazine
PREGNANCY CATEGORY: C
Not indicated for use in women
Contra-indicated in patients using any form of nitrates.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of avanafil in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric